Acute Decompensated Heart Failure: What You Need to Understand

2. What It Is

Acute decompensated heart failure is a rapid deterioration of the chronic heart failure syndrome, characterized by worsening symptoms and signs of congestion sufficient to require urgent evaluation, intravenous therapy, or hospitalization.

The term “decompensation” reflects a transition from the compensated state (in which the body’s adaptive mechanisms maintain relatively acceptable perfusion and fluid balance) to the decompensated state (in which fluid overload, raised filling pressures, and impaired organ perfusion exceed the body’s ability to compensate). This transition may be gradual (over days to weeks) or acute (over hours, as in flash pulmonary edema from hypertensive emergency).

ADHF is not a single disease. It is a presentation that can arise from any type of underlying heart failure (HFrEF, HFpEF, HFmrEF), precipitated by identifiable triggers in the majority of cases. In the ADHERE registry of more than 100,000 ADHF hospitalizations, only 35% of patients with ADHF had previously normal LV function 5 / Solid .

Hemodynamic profiles (the Stevenson classification)

The treating physician’s first task in ADHF is to classify the patient hemodynamically. Steven Stevenson at UCLA developed a bedside framework based on two axes:

Volume status (wet vs dry): Is the patient congested (raised filling pressures, JVD, edema, crackles) or euvolemic/depleted?

Perfusion (warm vs cold): Is the patient warm (adequate peripheral perfusion) or cold (poor perfusion: cool extremities, narrow pulse pressure, altered mental status, low urine output)?

This creates four profiles:

• Warm and Wet (Profile B): The most common ADHF presentation (approximately 70% of cases). Congested but adequate perfusion. IV diuresis is the primary treatment.
• Cold and Wet (Profile C): Congested and poorly perfused. Often requires inotropic support (dobutamine, milrinone) in addition to diuresis. Higher mortality.
• Cold and Dry (Profile L): Low output without congestion. Rare; represents forward failure without volume overload. Vasopressin excess, excessive diuresis, or tamponade physiology. Most dangerous.
• Warm and Dry (Profile A): Not ADHF; this is the compensated state.

Identifying the profile determines the treatment approach and the monitoring intensity needed.

3. The Mechanism

Why decompensation happens

Chronic heart failure is a pressure-volume system under constant neurohormonal stress. Decompensation occurs when a precipitating factor shifts the system past its compensatory capacity. The precipitating factors fall into recognizable categories:

1. Medication non-adherence: Missing doses of diuretics, ACE inhibitors, or beta-blockers is the most common trigger. In the OPTIMIZE-HF registry, approximately 25% of ADHF hospitalizations were attributed to medication non-adherence 5 / Solid .

2. Dietary sodium excess: A high-sodium meal (fast food, restaurant food, processed snacks) increases extracellular volume, raises preload, and can push a marginally compensated patient into decompensation within 24-48 hours.

3. New-onset or uncontrolled atrial fibrillation: Loss of the atrial kick reduces stroke volume by 20-25%. Tachycardia shortens diastolic filling time, reducing preload further. In a patient with already impaired LV function, this double insult triggers pulmonary edema rapidly.

4. Ischemia or infarction: New MI or ischemia reduces LV contractility acutely, causing sudden increase in filling pressures.

5. Hypertensive urgency: Marked blood pressure elevation increases afterload, reducing stroke volume and raising filling pressures. Flash pulmonary edema from a hypertensive emergency is a distinct subtype of ADHF.

6. Infection/fever: Increased metabolic demand, tachycardia, and direct myocardial depression from sepsis increase cardiac work and filling pressures.

7. Pulmonary embolism: Acute RV pressure overload from PE can precipitate right-sided decompensation and decrease LV filling through interventricular dependence.

8. Medication additions: NSAIDs (sodium and water retention), calcium channel blockers (negative inotropy in HFrEF), thiazolidinediones (fluid retention), and alcohol all worsen HF.

The pathophysiology of congestion

Fluid overload in ADHF results from RAAS activation, reduced renal perfusion, and aldosterone-driven sodium retention. As LV end-diastolic pressure rises above 18-20 mmHg, pulmonary capillary wedge pressure rises, and fluid transudates across the pulmonary capillary membrane into the alveolar space. The Starling forces are overwhelmed: capillary oncotic pressure cannot overcome the raised hydrostatic pressure, and the alveoli fill.

The sequence: raised LVEDP leads to raised LA pressure, raised pulmonary venous pressure, raised pulmonary capillary pressure, and finally pulmonary edema. In ADHF with hypertension, this cascade can occur within minutes: the patient is fine at midnight and in extremis at 2 a.m.

4. How We Diagnose

ADHF is primarily a clinical diagnosis, confirmed by biomarkers and imaging. The diagnostic approach must run in parallel with initial treatment.

Clinical assessment

Symptoms: acute dyspnea, orthopnea, paroxysmal nocturnal dyspnea, acute decrease in exercise tolerance, weight gain, abdominal discomfort from hepatic congestion.

Signs: raised JVP (above 8-10 cm H2O), S3 gallop, bilateral crackles, pitting edema, ascites in severe cases. In Profile C patients: cold and clammy extremities, narrow pulse pressure (less than 25% of systolic BP), altered mental status.

BNP and NT-proBNP

BNP above 100 pg/mL or NT-proBNP above 300 pg/mL has high sensitivity for ADHF in the undifferentiated dyspneic patient. The BREATHING-NOT-PROPERLY study: BNP above 100 pg/mL had sensitivity 90%, specificity 73%, positive predictive value 79% for acute heart failure 5 / Solid . In the REDHOT II trial, BNP-guided discharge decisions reduced 90-day events 4 / Promising .

NT-proBNP thresholds are age-stratified: below 50 years (<450 pg/mL is low probability), 50-75 years (<900 pg/mL), above 75 years (<1,800 pg/mL) 5 / Solid .

Chest radiograph

Classic ADHF findings: cardiomegaly, interstitial edema (Kerley B lines at the costophrenic angles), alveolar edema (“bat-wing” pattern), pleural effusions (typically right-sided or bilateral). Cephalization of pulmonary vasculature (upper lobe vessel prominence) indicates raised pulmonary venous pressure.

Echocardiography

Point-of-care ultrasound (POCUS) in the ED is increasingly used to rapidly assess LVEF, IVC size (IVC dilation above 2.1 cm with less than 50% inspiratory collapse correlates with RA pressure above 10 mmHg), and to identify pleural effusions. A formal TTE should be performed for all patients with new ADHF or significant change from prior imaging.

The EVEREST trial’s non-ultrasound lesson

A crucial diagnostic insight: chest radiograph may be normal in up to 20% of patients with ADHF. The cardiomegaly may not be acute; the interstitial edema may not yet be visible. Clinical judgment, BNP, and POCUS together are more reliable than the CXR alone in borderline presentations.

5. The Evidence

IV diuresis: the DOSE trial

The DOSE trial (Diuretic Optimization Strategies Evaluation) enrolled 308 patients with ADHF and tested low-dose vs high-dose furosemide and bolus vs continuous infusion 5 / Solid .

High-dose furosemide (2.5 times the outpatient oral dose, given IV) versus low-dose (1:1 oral-to-IV conversion): high-dose produced greater urine output and greater weight loss at 72 hours, with no significant difference in creatinine change. Patients in the high-dose group had greater symptom relief (global assessment score: p = 0.06, borderline significant). Bolus vs continuous infusion: no significant difference. Key takeaway: use high-dose IV furosemide. The 1:1 oral-to-IV dose conversion underestimates what is needed for decongestion.

Practical conversion: IV furosemide bioavailability is approximately twice oral. A patient on furosemide 80 mg PO twice daily should receive at least 80 mg IV push as a starting dose, with escalation if response is inadequate (urine output less than 200 mL/hour or less than 500 mL over 2 hours). Torsemide and bumetanide are alternatives for patients with poor furosemide absorption.

Ultrafiltration: the CARRESS-HF trial

CARRESS-HF compared ultrafiltration (mechanical fluid removal via a dialysis-like circuit) versus stepped pharmacological diuretic therapy in ADHF patients with cardiorenal syndrome 5 / Solid . Ultrafiltration was not superior and led to worse creatinine outcomes. Ultrafiltration has a limited role in ADHF; it is reserved for patients with diuretic resistance and worsening renal function on escalating diuretics.

Vasodilators: nesiritide and nitroglycerin

Nesiritide (recombinant BNP, Natrecor) was approved for ADHF based on hemodynamic improvement. The ASCEND-HF trial enrolled 7,141 patients and found no benefit in dyspnea, mortality, or readmission with nesiritide versus placebo 5 / Solid . Nesiritide is not routinely used in ADHF.

Intravenous nitroglycerin reduces preload (and afterload at high doses) and is appropriate for hypertensive ADHF (Profile B/C with hypertension). It reduces pulmonary capillary wedge pressure rapidly and is the agent of choice for flash pulmonary edema from hypertensive emergency concurrent with ADHF. Nitroprusside is used in advanced centers for severe afterload reduction in cardiogenic shock with hypertension; it requires invasive monitoring.

Inotropes: the SURVIVE trial

For Profile C patients (cold and wet) requiring cardiac output augmentation, dobutamine and milrinone are the primary inotropes. The SURVIVE trial randomized 1,327 patients with ADHF and low cardiac output to levosimendan versus dobutamine: no mortality difference at 180 days 5 / Solid . Levosimendan is available in Europe and some other countries; it is not FDA-approved in the United States.

Inotropes carry arrhythmia risk (particularly for dobutamine, which is beta-1 agonist-driven) and are not palliative home medications. Continuous outpatient inotrope infusion is considered palliative or bridge therapy in Stage D HFrEF, with a documented survival disadvantage at six months in the FIRST trial.

Preventing the 30-day readmission

The 30-day readmission rate for ADHF hospitalization has been approximately 20-25% in US data 5 / Solid . Hospital readmission penalties under CMS incentivized hospitals to address this, with some improvement over the subsequent decade.

What reduces readmission:

• GDMT optimization during hospitalization (starting or uptitrating the four-drug protocol before discharge).
• Early post-discharge follow-up (within 7-14 days).
• Patient and family education on daily weights, sodium restriction, and the threshold for calling in.
• Transitional care programs.

The STRONG-HF trial addressed the first point: rapid uptitration of GDMT during and immediately after ADHF hospitalization reduced 180-day readmission plus mortality by 34% 5 / Solid 02076-1). This trial changed practice: the old caution of “get them stable first, then start meds” was replaced by “start meds during hospitalization when hemodynamically stable.”

6. The Patient Experience

For the patient, ADHF is terrifying. The sensation of drowning while lying in one’s own bed, the inability to complete a sentence without gasping, the confusion and panic at 3 a.m.: these are among the most distressing experiences in all of medicine. Family members are often more distressed than the patient.

The relief from IV diuresis is equally dramatic in the other direction. A patient who arrived unable to speak in full sentences is often sitting up eating lunch four hours after the first IV push, looking sheepish about what seemed like a life-ending emergency. This rapid reversal is both a relief and a dangerous pattern: it creates false confidence that the crisis is over.

The crisis is not over. It is paused. The same pathophysiology that led to decompensation will reassert itself unless the underlying drivers are addressed. The 30-day readmission data represents patients for whom the crisis paused but the repair was not done.

The discharge conversation matters as much as the hospital treatment. Patients who understand:

• That their weight is the most sensitive early warning sign of recurrent decompensation
• That a 2-lb overnight weight gain is a call to the cardiologist, not a “wait and see”
• That missing even a few days of furosemide can rebuild the fluid load they just spent three days removing
• That salt in one restaurant meal can negate two days of diuretic work

…are patients who are less likely to be back in 30 days.

CardioMEMS (Abbott), an implantable PA pressure sensor approved by FDA under PMA for heart failure patients previously hospitalized, allows remote monitoring of pulmonary artery pressure. In the CHAMPION trial, CardioMEMS-guided management reduced heart failure hospitalization by 28% at six months 5 / Solid . The device is available at major heart failure centers including Northwestern Memorial (Chicago) and Carle Foundation Hospital (Urbana). Rural patients in central Illinois face transport barriers to obtaining and managing this device.

7. Decisions and Trade-Offs

Diuresis vs renal function: the cardiorenal tension

Aggressive diuresis improves congestion but reduces renal perfusion. The creatinine often rises during ADHF hospitalization. The question clinicians face: is this worsening creatinine harmful (tubular injury from reduced perfusion) or an acceptable marker of volume removal?

The evidence from DOSE and CARRESS-HF suggests that moderate creatinine rise during aggressive diuresis (less than 0.3-0.5 mg/dL) does not indicate meaningful tubular injury and is associated with better decongestion outcomes. However, a patient who arrives with creatinine 2.0 and climbs to 3.2 despite adequate urine output may be experiencing true cardiorenal syndrome type 1 (acute heart failure causing acute kidney injury), requiring a different approach.

Urine sodium and urine output monitoring guide adequacy of diuretic response: urine sodium above 50-70 mEq/L with a furosemide dose indicates adequate loop diuretic response. If urine sodium is below 50 mEq/L despite adequate furosemide dose, consider adding a thiazide (metolazone 2.5-5 mg) for sequential nephron blockade.

When to add inotropes

Profile C patients (cold and wet) present the most complex management challenge. Inotropes increase cardiac output and shift the patient toward warm-and-wet (Profile B) where diuresis is possible. But inotropes also increase myocardial oxygen demand, provoke arrhythmias, and carry the risk of being started and never stopped (becoming a palliative bridge rather than a bridge to recovery).

The INTERMACS classification helps: an INTERMACS 2 patient (progressive decline despite inotropes) needs LVAD or escalation. An INTERMACS 4 patient (resting symptoms on oral therapy, no inotropes needed) can be managed more conservatively.

Home IV diuresis

For frequent ADHF readmitters, home IV diuresis via a PICC line or port is an option that reduces hospitalization burden. Community programs in Illinois vary in availability: Chicago-area home infusion agencies provide this; rural central Illinois patients face more limited options. The clinical prerequisites are a reliable caregiver, stable social situation, and a monitoring plan for creatinine and potassium during the diuresis period.

Discharge readiness criteria

Standard discharge criteria include: (1) dry weight achieved and stable for 24 hours; (2) oral diuretic dose established and tolerated; (3) creatinine stable or improving; (4) oxygen saturation above 94% on room air or home oxygen (for appropriate patients); (5) follow-up appointment confirmed within 7-14 days; (6) education completed for daily weights and sodium restriction; (7) GDMT optimization reviewed and documented.

8. The SDE Synthesis

ADHF is the visible, catastrophic manifestation of what happens when chronic heart failure management fails. It is expensive: the average hospitalization cost for ADHF exceeds $25,000. It is a trauma: patients who survive one ADHF hospitalization are at 20% risk of dying within one year 5 / Solid . It is, in most cases, at least partially preventable.

The SDE Cohort model exists specifically to prevent ADHF readmissions and to reduce the frequency of de novo ADHF decompensations. The platform provides:

• Daily weight monitoring with alert thresholds (2 lb/day or 5 lb/week triggers a team contact)
• Remote blood pressure monitoring with titration guidance
• Medication adherence tracking (refill reminders, 90-day supply coordination)
• Proactive biomarker monitoring (BNP/NT-proBNP every 3 months in high-risk patients)

For patients with recurrent ADHF despite maximal guideline-directed medical therapy, CardioMEMS implantation at a qualified heart failure center is an evidence-based option. The SDE Executive tier provides access facilitation for this procedure and for post-ADHF advanced heart failure workup.

The man from Peoria missed his furosemide for three days because the prescription ran out and refilling it felt like too much trouble. That is a solvable problem. It is also a reminder that the most advanced heart failure treatments in the world cannot help a patient who cannot get to a pharmacy.

The gap between the evidence and the outcome is often not a biological gap. It is a systems gap. The SDE platform is designed to close it.